xista science ventures — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Hephaistos-Pharmahephaistos-pharma.frinMay 2024✓ verified
HEPHAISTOS is a biopharmaceutical company developing third-generation innate immune boosters (TLR4 agonists) that convert myeloid-rich, immunotherapy-resistant tumors into immunotherapy-responsive tumors.
BiotechMedical DevicesOrsay, FR
Martine Caroff(Scientific Founder)inFrederic Caroff(CEO)inFrederique Brune(CDO)inStephan Braun(CMO)inJerome Kerzerho(CSO)inChristel Lonneux(CFO and HR)in
Co-investorsElaiaAngels SantéFemmes Business Angels
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.